• 1
    Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156: 271278.
  • 2
    Dienstag JL, Ghany MG, Morgan TR et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology 2011; 54: 396405.
  • 3
    De Meyer S, Dierynck I, Ghys A et al. Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial. Hepatology 2012; 56: 21062115.
  • 4
    Ingiliz P, Rockstroh JK. HIV-HCV co-infection facing HCV protease inhibitor licensing: implications for clinicians. Liver Int 2012; 32: 11941199.
  • 5
    Guedj J, Dahari H, Pohl RT, Ferenci P, Perelson AS. Understanding silibinin's modes of action against HCV using viral kinetic modeling. J Hepatol 2012; 56: 10191024.
  • 6
    Ferenci P, Scherzer TM, Kerschner H et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 2008; 135: 15611567.
  • 7
    Wedemeyer H, Jensen DM, Godofsky E et al. Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents. Hepatology 2012; 56: 23982403.
  • 8
    Bartlett J, Gulick R, Hirsch M, Lane H. HHS panel on antiretroviral guidelines for adults and adolescents – a working group of the OARAC. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 12 February 2013.
  • 9
    Zeuzem S, Andreone P, Pol S et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 24172428.
  • 10
    Fontaine H, Hézode C, Dorival C et al. for the ANRS CO 20 CUPIC study group. SVR12 rates and safety of triple therapy including telaprevir or boceprevir in 485 cirrhotic non responders treated in the French Early Access Program (ANRS CO20-CUPIC). EASL 48th Annual Meeting, 24–28 April 2013.
  • 11
    Miailhes P, Lacombe K, Arends JE et al. the ANRS CO13-HEPAVIH and ESCMID European Study Group on Viral Hepatitis. Triple therapy with telaprevir (TPV) or boceprevir (BOC) in cirrhotic HIV/HCV infected patients: real life on-treatment data from Europe. Conference of the European AIDS Clinical Society 2013.
  • 12
    Berg T, Andreone P, Pol S et al. Predictors of virologic response with telaprevir-based combination TREATMENT in HCV genotype 1-infected patients with prior peginterferon/ribavirin treatment failure: post-hoc analysis of the phase III REALIZE study. 62th Annual Meeting of the AASLD, San Francisco, CA, 6–9 November 2011.
  • 13
    Gordon SC, Reddy KR, Jacobson IM et al. Boceprevir plus peginterferon alpha-2b/ribavirin in chronic hepatitis C genotype 1: impact of baseline viral load on sustained virologic response. J Clin Gastroenterol 2014; 48: 435443.
  • 14
    Sarrazin C, Kieffer TL, Bartels D et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132: 17671777.
  • 15
    HCV Phenotype Working Group HDDAG. Clinically relevant HCV drug resistance mutations. Ann Forum Collab HIV Res 2012; 14: 110.
  • 16
    Jacobson IM, Gordon SC, Kowdley KV et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 18671877.
  • 17
    Zeuzem S, Dusheiko GM, Salupere R et al. Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2013). Washington DC, November 2013 [Abstract 1085].
  • 18
    Dieterich D, Rockstroh J, Orkin C et al. Simeprevir (TMC435) plus peginterferon/ribavirin in patients co-infected with HCV genotype-1 andHIV-1: primary analysis of the C212 study. 14th European AIDs Conference (EACS 2013). Brussels, October 2013 [Abstract PS9/5].
  • 19
    Rockstroh R, Nelson M, Soriano V et al. STARTVerso 4 phase III trial of faldaprevir once-daily plus peg interferon alfa-2a and ribavirin (PR) in patients with HIV and HCV genotype 1 coinfection. 14th European AIDS Conference. Brussels, October 2013 [Abstract 9/7].
  • 20
    British HIV Association. Guidelines for the management of hepatitis viruses in adults infected with HIV 2013. HIV Med 2013; 14 (Suppl 4): 171.